Aktienanalyse zu Avalo Therapeutics, Inc. (AVTX)AVTXAvalo Therapeutics, Inc.

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1β mAb, targeting inflammatory diseases. AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1β (IL-1β) with high affinity and neutralizes its activity. IL-1β is a central driver in the inflammatory process. Overproduction or dysregulation of IL-1β is implicated in many autoimmune and inflammatory diseases. IL-1β is a major, validated target for therapeutic intervention. There is evidence that inhibition of IL-1β could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology, and rheumatology. AVTX-009 is in the Phase II LOTUS trial for hidradenitis suppurativa (HS). It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Avalo Therapeutics Inc is a good buy right now due to its current price of $19.59, which is significantly lower than the average analyst price target of $38, indicating a potential upside of over 93%. Additionally, the stock has shown a strong 1-year change of +117.18%, reflecting positive long-term growth. However, a key risk is the negative earnings per share (EPS) of -0.83 reported in the last earnings, which could impact investor sentiment.